Status:
TERMINATED
Resveratrol Trial for Relief of Pain in Pseudoachondroplasia
Lead Sponsor:
The University of Texas Health Science Center, Houston
Conditions:
Pseudoachondroplasia
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine if self-administered oral resveratrol can dampen joint pain for individuals with pseudoachondroplasia compared to placebo. Another goal of this study is to ev...
Eligibility Criteria
Inclusion
- The diagnosis of pseudoachondroplasia is based on clinical assessment either in person or by photographic review by skeletal dysplasia specialist (JTH),
- Healthy beyond pseudoachondroplasia associated complications,
Exclusion
- Current use of resveratrol
- Current use of blood thinners, lovastatin, ketoconazole, itraconazole, fexofenadine and triazolam.
- Other non-pseudoachondroplasia related health conditions, e.g. cancers.
- Pregnancy or breastfeeding. Women must use adequate contraception during the study.
- Participation in another clinical study and/or using investigational agents.
- Use of Non-steroid anti-inflammatory (NSAIDs) or aspirin.
- Current use of Alfentanil, Cyclosporine, Dihydroergotamine, Dofetilide, Ergotamine, Fentanyl, Flibanserin, Oxycodone, Pimavanserin, Pimozide, Quinidine, Saquinavir, Sirolimus, Tacrolimus, Temsirolimus, Theophylline, Tizanidine, Thioridazine, Fosphenytoin, Phenytoin or Warfarin.
- Baseline level of pain of 2 or higher on 10 point scale.
- Platelet count below 50,000 per ul on baseline complete blood count (CBC).
Key Trial Info
Start Date :
June 29 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 28 2020
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT03866200
Start Date
June 29 2019
End Date
October 28 2020
Last Update
December 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Texas Health Science Center
Houston, Texas, United States, 77030